BOD to acquire Aqua Phase following placement
Earlier today, our cannabis investment, BOD Australia (ASX:BOD) entered a trading halt on the back of an acquisition and placement.
BOD has agreed to acquire ‘Aqua Phase’, a process technology to increase the bioavailability of cannabis compounds, along with all intellectual property, confidential information, records, goodwill and branding.
We will provide our commentary on the acquisition once further details are made available.
We’re also keen to see what progress has been made on two clinical trials that BOD is advancing, in which first patients were recruited last quarter:
- Insomnia (Phase IIb)
- Long-COVID (Open label, “Proof of Concept”)
